NCT07733362 Assessment of the Immunomodulatory Potential of Spirulina Blue Protein Capsule on Immunomodulation in Healthy Volunteers
| NCT ID | NCT07733362 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Phayao |
| Condition | Healthy Volunteers |
| Study Type | INTERVENTIONAL |
| Enrollment | 54 participants |
| Start Date | 2026-08-15 |
| Primary Completion | 2026-11-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 54 participants in total. It began in 2026-08-15 with a primary completion date of 2026-11-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study is a randomized, double-blind, placebo-controlled clinical trial designed to evaluate the safety and immunomodulatory effects of Spirulina Blue Protein capsules in healthy adults. Participants will be randomly assigned to receive placebo, 200 mg/day, or 1,000 mg/day of Spirulina Blue Protein capsules for 12 weeks. The study will assess changes in immune cell populations (CD4+, CD8+, and natural killer cells), circulating cytokine levels, hematological and biochemical parameters, and the occurrence of adverse events. The findings will provide evidence regarding the safety and potential immunomodulatory benefits of Spirulina Blue Protein supplementation in healthy individuals and support the development of evidence-based functional food and nutraceutical products.
Eligibility Criteria
Inclusion Criteria: * Healthy male or female adults aged 25-60 years. * Body mass index (BMI) between 18.5 and 24.9 kg/m². * Able and willing to provide written informed consent. * Willing and able to comply with all study procedures and scheduled visits Exclusion Criteria: * History of diseases affecting the immune system or metabolism, including cardiovascular disease, diabetes mellitus, liver disease, kidney disease, autoimmune disorders, or chronic inflammatory diseases. * Abnormal laboratory findings outside the reference range, including complete blood count, liver function tests, or renal function tests. * Current use of medications or dietary supplements that may affect the study outcomes. * Known allergy to Spirulina, algae-containing dietary supplements, or any component of the study capsules. * Pregnant or breastfeeding women.
Contact & Investigator
Chutamas Thepmalee, PhD
PRINCIPAL INVESTIGATOR
School of Medical Sciences, University of Phayao
Frequently Asked Questions
Who can join the NCT07733362 clinical trial?
This trial is open to participants of all sexes, aged 25 Years or older, up to 60 Years, studying Healthy Volunteers. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07733362 currently recruiting?
Yes, NCT07733362 is actively recruiting participants. Contact the research team at th.chutamas@gmail.com for enrollment information.
Where is the NCT07733362 trial being conducted?
This trial is being conducted at Phayao, Thailand.
Who is sponsoring the NCT07733362 clinical trial?
NCT07733362 is sponsored by University of Phayao. The principal investigator is Chutamas Thepmalee, PhD at School of Medical Sciences, University of Phayao. The trial plans to enroll 54 participants.